People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NQ PE Project Durm Parent, L.P. | — | Other | Series C | $79.9M | $925.2M | 2022 |
| NQ PE Project Stingray Parent, L.P. | — | Pharmaceuticals | Series A | $11.4M | $131.7M | 2022 |
Jeffrey Edwards at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Edwards on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Sorensen | 1 | 4 |
| Vern Davenport | 1 | 3 |
| Ryan Applegate | 1 | 1 |
| Ashton Poole | 1 | 1 |
| Carl Hellman | 1 | 1 |
| E. Ashton Poole | 1 | 1 |
| (the "GP") NQ PE Project Stingray Parent GP, Ltd. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.